SIREN : 808701049
GENE HOLDING is a French company founded 11 years ago, specialized in the sector Activités des sociétés holding. Based in FRANCONVILLE (95130), this company of category PME shows in 2025 a revenue of 3.9 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3 898 052 € | 3 575 140 € | 2 904 302 € | 2 467 537 € | 1 543 099 € | 913 594 € | 1 288 522 € | 277 600 € | 244 227 € |
| Net income | 430 693 € | 516 697 € | 605 633 € | 672 569 € | 557 521 € | 462 970 € | 966 006 € | 409 258 € | 253 192 € |
| EBITDA | -46 088 € | -109 517 € | -182 518 € | -55 861 € | -56 674 € | -95 746 € | -84 361 € | 18 540 € | 23 182 € |
| Net margin | 11.0% | 14.5% | 20.9% | 27.3% | 36.1% | 50.7% | 75.0% | 147.4% | 103.7% |
In 2025, GENE HOLDING achieves revenue of 3.9 M€. Over the period 2017-2025, the company shows strong growth with a CAGR (compound annual growth rate) of +41.4%. Vs 2024: +9%. After deducting consumption (138 k€), gross margin stands at 3.8 M€, i.e. a rate of 96%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches -46 k€, representing -1.2% of revenue. Negative EBITDA means operations do not cover current expenses: concerning situation. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 431 k€, i.e. 11.0% of revenue. This profit can be retained or distributed to shareholders.
3 898 052 €
3 760 552 €
-46 088 €
73 380 €
430 693 €
-1.2%
The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 64%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Cash flow represents 8.0% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. Satisfactory level allowing partial financing of growth.
0.0%
63.528%
7.984%
0.0
36.7%
In 2025, the debt ratio of GENE HOLDING (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.
In 2025, the financial autonomy of GENE HOLDING (63.5%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2025, the repayment capacity of GENE HOLDING (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.
The liquidity ratio (= Current assets / Current liabilities) stands at 231.93. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
231.927
0.0
In 2025, the liquidity ratio of GENE HOLDING (231.93) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
In 2025, the interest coverage of GENE HOLDING (0.0x) ranks above the median of the sector. This ratio indicates how many times operating income covers interest expenses. This comfortable position offers an appreciable safety margin.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 147 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 69 days. The gap of 78 days means the company finances its customers for over a month before being paid relative to supplier payments. This weighs on cash flow. Overall, WCR represents 68 days of revenue, i.e. 731 k€ to permanently finance. Over 2017-2025, WCR increased by +5520%, requiring additional financing.
731 275 €
147 j
69 j
0 j
68 j
Indicative estimate only : the number of comparable transactions in this sector is limited (20 transactions). This range of 1 214 084€ to 5 045 871€ is provided for information purposes only and requires in-depth analysis to be confirmed.
This estimate is based on the analysis of 20 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare GENE HOLDING with other companies in the same sector:
Voir toutes les statistiques du secteur Activités des sociétés holding
The revenue of GENE HOLDING in 2025 is 3.9 M€.
Yes, GENE HOLDING generated a net profit of 431 k€ in 2025.
The headquarters of GENE HOLDING is located in FRANCONVILLE (95130), in the department Val-d'Oise.
The tax return of GENE HOLDING is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
GENE HOLDING operates in the sector Activités des sociétés holding (NAF code 64.20Z). See the 'Sector positioning' section above to compare the company with its competitors.